189 related articles for article (PubMed ID: 12171874)
1. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
3. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.
Tillman DM; Petak I; Houghton JA
Clin Cancer Res; 1999 Feb; 5(2):425-30. PubMed ID: 10037193
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
Turner PK; Houghton JA; Petak I; Tillman DM; Douglas L; Schwartzberg L; Billups CA; Panetta JC; Stewart CF
Cancer Chemother Pharmacol; 2004 Mar; 53(3):253-60. PubMed ID: 14648016
[TBL] [Abstract][Full Text] [Related]
5. p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.
Petak I; Tillman DM; Houghton JA
Clin Cancer Res; 2000 Nov; 6(11):4432-41. PubMed ID: 11106264
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Cao S; Troutt AB; Rustum YM
Cancer Res; 1998 Apr; 58(8):1695-9. PubMed ID: 9563485
[TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Marshall JL; Richmond E; DeLap RJ
Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
9. Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies.
Bruckner HW; Petrelli NJ; Stablein D; Novak J; Mayer R
NCI Monogr; 1987; (5):179-84. PubMed ID: 3501539
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
11. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
12. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
Ferraresi V; Giampaolo MA; Gabriele A; Mansueto G; Buccilli A; Giannarelli D; Ciccarese M; Gamucci T
J Exp Clin Cancer Res; 2005 Jun; 24(2):187-96. PubMed ID: 16110750
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
Kogure T; Ueno Y; Iwasaki T; Shimosegawa T
Cancer Chemother Pharmacol; 2004 Apr; 53(4):296-304. PubMed ID: 14689231
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Al-Batran SE; Atmaca A; Schleyer E; Pauligk C; Hosius C; Ehninger G; Jäger E
Cancer; 2007 May; 109(9):1897-904. PubMed ID: 17377918
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Cao S; Frank C; Shirasaka T; Rustum YM
Clin Cancer Res; 1995 Aug; 1(8):839-45. PubMed ID: 9816053
[TBL] [Abstract][Full Text] [Related]
17. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin, and phenylbutyrate.
Huang Y; Horvath CM; Waxman S
Cancer Res; 2000 Jun; 60(12):3200-6. PubMed ID: 10866311
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Grem JL; McAtee N; Murphy RF; Balis FM; Cullen E; Chen AP; Hamilton JM; Steinberg SM; Quinn M; Sorensen JM; Arbuck SG; Lawrence D; Pang J; Allegra CJ
Clin Cancer Res; 1997 Jul; 3(7):1125-34. PubMed ID: 9815792
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.
Madajewicz S; Petrelli N; Rustum YM; Campbell J; Herrera L; Mittelman A; Perry A; Creaven PJ
Cancer Res; 1984 Oct; 44(10):4667-9. PubMed ID: 6331882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
